Please Scroll Down to See Forums Below 
I was doing a bit of research on the net - trying to find a good way to lower progestin. It seemed that the best one was cabergoline/dostinex. A little later in my research I saw that there was some risk associated with heart valve damage, but this was at a MUCH higher dose than we use. I found a study showing that the doses used to treat hyperprolactinaemia , which is dosed the exact same dosing have been doing (.5mg/E3D is safe), and that there was NO increased risk of heart damage.
------------------------------------------ the study
Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease
Ammar Wakil, Alan S Rigby1, Andrew L Clark2, Anna Kallvikbacka-Bennett2 and Stephen L Atkin3
Michael White Diabetes Centre, Hull Royal Infirmary, Brocklehurst Building, 220-236 Anlaby Road, Hull HU3 2RW, UK1 Department of Academic Cardiology, University of Hull, Hull, UK2 Castle Hill Hospital, Castle Road, Cottingham, UK3 Department of Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull, UK
(Correspondence should be addressed to A Wakil; Email: [email protected])
Objective: Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease. However, the dose of cabergoline used to treat hyperprolactinaemia is considerably less than that used in Parkinson's disease.
Design and methods: A cross-sectional comparative assessment. Forty-four patients treated with cabergoline for hyperprolactinaemia underwent transthoracic echocardiography and were compared with 566 sequential subjects complaining of palpitations, taken from a contemporary echocardiography database.
Results: The mean cumulative dose of cabergoline in the cases was 311 mg. There was no significant, severe or moderate, right- or left-sided valvular regurgitation in either group. Left heart: in the mitral and aortic valves, the rate of mild and trivial valvular regurgitation was not different between the two groups. Right heart: mild tricuspid and pulmonary regurgitation on colour Doppler alone was increased significantly in the cabergoline group, odds ratios of 3.1 and 7.8 respectively (95% confidence interval 1.0–9.6 and 0.8–78.4, P=0.04 and P<0.0001 respectively).
Conclusion: Cabergoline at doses sufficient to suppress hyperprolactinaemia for a period of 3–4 years is not associated with an increased risk of clinically significant valvular regurgitation.
-------------------------------------------------------- reference URL
(www).eje-online.(org)/cgi/content/abstract/159/4/R11
(sorry, not enough posts, so you have to remove the parenthesis from the URL)
Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease -- Wakil et al. 159 (4): R11 -- European Journal of Endocrinology[/url]
---------------------------------------------------a few last words
(I will be posting this to a few forums, so don't tell me that I copied this)
Now we can prevent all those progestin sides without worrying about our heart!!!
------------------------------------------ the study
Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease
Ammar Wakil, Alan S Rigby1, Andrew L Clark2, Anna Kallvikbacka-Bennett2 and Stephen L Atkin3
Michael White Diabetes Centre, Hull Royal Infirmary, Brocklehurst Building, 220-236 Anlaby Road, Hull HU3 2RW, UK1 Department of Academic Cardiology, University of Hull, Hull, UK2 Castle Hill Hospital, Castle Road, Cottingham, UK3 Department of Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull, UK
(Correspondence should be addressed to A Wakil; Email: [email protected])
Objective: Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease. However, the dose of cabergoline used to treat hyperprolactinaemia is considerably less than that used in Parkinson's disease.
Design and methods: A cross-sectional comparative assessment. Forty-four patients treated with cabergoline for hyperprolactinaemia underwent transthoracic echocardiography and were compared with 566 sequential subjects complaining of palpitations, taken from a contemporary echocardiography database.
Results: The mean cumulative dose of cabergoline in the cases was 311 mg. There was no significant, severe or moderate, right- or left-sided valvular regurgitation in either group. Left heart: in the mitral and aortic valves, the rate of mild and trivial valvular regurgitation was not different between the two groups. Right heart: mild tricuspid and pulmonary regurgitation on colour Doppler alone was increased significantly in the cabergoline group, odds ratios of 3.1 and 7.8 respectively (95% confidence interval 1.0–9.6 and 0.8–78.4, P=0.04 and P<0.0001 respectively).
Conclusion: Cabergoline at doses sufficient to suppress hyperprolactinaemia for a period of 3–4 years is not associated with an increased risk of clinically significant valvular regurgitation.
-------------------------------------------------------- reference URL
(www).eje-online.(org)/cgi/content/abstract/159/4/R11
(sorry, not enough posts, so you have to remove the parenthesis from the URL)
Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease -- Wakil et al. 159 (4): R11 -- European Journal of Endocrinology[/url]
---------------------------------------------------a few last words
(I will be posting this to a few forums, so don't tell me that I copied this)
Now we can prevent all those progestin sides without worrying about our heart!!!
